Endothelial Function & Cardiac Output in RV Pacing

Status Completed

Clinical Trial Summary

Pacing from the right ventricle (as is current practice in patients implanted with permanent pacemakers for bradycardia), has been associated with worse outcomes particularly in heart failure patients. Recent clinical trials suggest that chronic right ventricular pacing (VP) is associated with worsening heart failure, increased strokes and atrial fibrillation. Hemodynamically, right VP results in delayed activation and contraction of the LV which can give rise to functional mitral regurgitation, shortened diastolic filling time and thus reduced coronary filling, as well as abnormal arterial pulsatile flow. The mechanisms for the deleterious effects of right VP in heart failure patients have not been previously investigated. Our aim of this study is therefore to investigate the hemodynamic effects of right VP in stable heart failure patients in terms of exercise cardiac output (CO, an important measure of myocardial function and prognosis), as well as endothelial function which may be deranged as a result of abnormal arterial pulsatile flow.

Clinical Trial Description

Study Aims The aim of this study is to investigate the effect of right ventricular pacing on CO at rest and exercise, and on endothelial function and B-type natriuretic peptide, BNP, in patients with heart failure.

Methods: Thirty patients with dual chamber pacemakers for sinus node disease will be recruited: 15 controls with normal LV function and 15 with stable impaired LV function (ejection fraction <40%). The pacemaker will be programmed to pace to back-up pacing at 55bpm in the atrial only (AAI, no right VP) for one week (baseline); and than programmed to overdrive pacing at 70-80bpm, randomised to either to dual chamber, DDD (sequential atrial and ventricular pacing) with a short AV delay (to ensure maximal right VP) or AAI (no RV pacing), for 1 week. There will be a crossover after a 1 week washout at backup AAI pacing at 55 bpm. Resting and exercise CO will be measured at the end of each pacing mode intervention using the Inocor system (a validated non invasive method of CO measurement, using inhaled inert gas equilibriums). Endothelial function will be measured non-invasively at the same time points, as will plasma BNP, a measure of LV strain. Patients with unstable heart failure or angina will be excluded.

Study Endpoints: Rest and exercise CO; and endothelial function and BNP with and without RV pacing, in patients with preserved and impaired LV function. ;

Study Design

Related Conditions & MeSH terms

Bradycardia

Clinical Trial Details

NCT number	NCT00508196
Study type	Interventional
Source	University of Dundee
Contact
Status	Completed
Phase	N/A
Start date	November 2006
Completion date	July 2007

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03922386` - Safety and Electrical Performances of XFINE Leads	N/A
Completed	`NCT03294018` - Heart Rate Changes Following the Administration of Sugammadex
Not yet recruiting	`NCT05649891` - Checklists Resuscitation Emergency Department	N/A
Not yet recruiting	`NCT05440071` - PoSt-market Assessment on Safety and Performance of J-sHAPed xFINE Lead
Completed	`NCT02153242` - The Effects of Selective Site Right Ventricular Pacing
Recruiting	`NCT01825473` - Study of Erythromycin in GER-Associated Apnea of the Newborn	N/A
Completed	`NCT00950287` - Detection of Neonatal Bradycardia	N/A
Completed	`NCT00721136` - Randomized Study of the Use of Warfarin During Pacemaker or ICD Implantation in Patients Requiring Long Term Anticoagulation	N/A
Completed	`NCT00286858` - Beluga - Clinical Observations of Automatic Algorithms for Cardiac Pacing
Completed	`NCT00158925` - The EASYTRAK EPI Clinical Investigation	Phase 3
Completed	`NCT00180557` - Austria Study - Analysis of Difference Between Active and Passive Fixation Leads	Phase 4
Completed	`NCT01076348` - Model 4965 Post-Approval Study
Completed	`NCT04198220` - BIO\|STREAM.ICM Obesity
Recruiting	`NCT05298748` - The Effect of Womb Recordings on Maturation of Respiratory Control in Preterm Infants	N/A
Recruiting	`NCT04353960` - The Alaska Oculocardiac Reflex Study
Terminated	`NCT04093414` - Left Bundle Area Versus Selective His Bundle Pacing	N/A
Completed	`NCT03786640` - Abbott Brady 3T MRI PMCF
Recruiting	`NCT05935007` - Aveir DR Real-World Evidence Post-Approval Study
Recruiting	`NCT05932602` - AVEIR DR Coverage With Evidence Development (CED) Study
Recruiting	`NCT04075084` - Observation of Clinical Routine Care for Patients With BIOTRONIK Implantable Cardiac Monitors (ICMs)

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Endothelial Function and Cardiac Output in RV Pacing

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms